Company: KROS
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001664710-25-000071
Chunk: 3

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 8-K
Item: Item 5.02
Chunk 3
---
 to this Current Report on Form 8-K and incorporated herein by reference.

Entry into Employment Agreement with Esther Cho

On August 6, 2025, the Company entered into an employment agreement with Esther Cho, the Company’s Senior Vice President, General Counsel (the “ Cho Employment Agreement”), effective as of August 6, 2025.

Ms. Cho, age 36, has served as our Senior Vice President, General Counsel since February 2023, and also serves as our Secretary. Prior to that, Ms. Cho served as our Head of Legal beginning in April 2020. Prior to joining us, Ms. Cho was an associate at Cooley LLP, where she represented life science companies in a wide variety of matters through all stages of their life cycle. Ms. Cho received a J. D. from Boston University School of Law and a B. A. in History from University of Pennsylvania.

The employment of Ms. Cho is “at will” and the Cho Employment Agreement continues until terminated by either party. Pursuant to the terms of the Cho Employment Agreement, Ms. Cho is entitled to an initial annual base salary of $460,000 and an annual discretionary bonus with a target amount equal to 40% of her annual base salary.

Ms. Cho is eligible to participate in the employee benefit plans generally available to the Company’s employees, and is subject to customary confidentiality covenants, as well as a non-competition and non-solicitation covenant for a period of 12 months following her termination of employment.

Ms. Cho is entitled to certain severance benefits, subject to specific requirements, including signing and not revoking a separation agreement and release of claims. Cause, change of control, disability and good reason are defined in the Cho Employment Agreement.

In the event Ms. Cho is terminated by the Company involuntarily without cause (and not due to death or disability) or she resigns for good reason, in each case, not in connection with a change of control, then Ms. Cho is entitled to cash severance equal to continued base salary payments for nine months and payment of COBRA premiums for up to nine months.

If within one month before or within 12 months following a change of control, Ms. Cho is terminated by the Company or successor involuntarily without cause (and not due to death or disability) or she resigns for good reason, Ms. Cho is entitled to the following: (a) cash severance equal to continued base salary payments for 12 months; (